BioSpace News Archive

Shape Memory Medical Inc. announced the completion of patient enrollment in AAA-SHAPE, the Company’s prospective, multicenter early feasibility safety study of the IMPEDE-FX RapidFill® Device when used for abdominal aortic aneurysm sac management during elective endovascular aneurysm repair.

Alnylam Pharmaceuticals, Inc. today announced positive results from a Phase 2 study of cemdisiran, an investigational RNAi therapeutic targeting the C5 component of the complement pathway, in development in collaboration with Regeneron Pharmaceuticals for the treatment of adult patients with immunoglobulin A nephropathy (IgAN).

bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the following upcoming investor conferences.

Neuronetics, Inc. (NASDAQ: STIM), announced today that they have received 510(k) clearance for their D-Tect™ MT Accessory, which is the latest innovation in NeuroStar’s commitment to simplify the motor threshold determination for physicians.

Theranica today announced the closing of its Series C funding round, with a first closing of $45 million.

Devyser has today been certified under the new, more comprehensive IVD Regulation that came into force on May 26, 2022.

Genome Insight, a cancer whole genome platform company, is launching a pilot program in Ajou University Medical Center to test the use of Whole Genome Sequencing (WGS) in routine cancer care setting.

Brand Institute is proud to announce its work with Mayne Pharma in developing the brand name HALOETTE®.

Chimerix today announced that is has signed a multi-year contract with the Biomedical Advanced Research and Development Authority (BARDA) in the U.S. Department of Health and Human Services’ Administration for Strategic Preparedness and Response (ASPR), for the delivery of up to 1.7 million treatment courses of tablet and suspension formulations of TEMBEXA® to the U.S. government.

The neuromodulation market has been expected to reach US$ 10.4 Bn and grow at a CAGR of 11.8% during the forecast period from 2021 to 2031.